Obio Pharmaceutical Holdings

Obio Pharmaceutical Holdings Limited is a Hong Kong-based biopharmaceutical company focused on the research and development of novel small molecule therapies for infectious and metabolic diseases. The company's pipeline includes TG-21, a cysteamine-based antiviral agent for the treatment of influenza, and DC-9703, a PPAR delta agonist targeting type 2 diabetes and dyslipidemia. Incorporated in the British Virgin Islands in 2002, Obio has established a portfolio of patents across several international jurisdictions, including the United States and South Africa. The company has historically engaged in academic collaborations and has been supported by private investments, including from the Singapore-based firm ICP Ltd.